Your browser doesn't support javascript.
loading
Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMR.
Kramer, Christopher M; DiMarco, John P; Kolm, Paul; Ho, Carolyn Y; Desai, Milind Y; Kwong, Raymond Y; Dolman, Sarahfaye F; Desvigne-Nickens, Patrice; Geller, Nancy; Kim, Dong-Yun; Maron, Martin S; Appelbaum, Evan; Jerosch-Herold, Michael; Friedrich, Matthias G; Schulz-Menger, Jeanette; Piechnik, Stefan K; Mahmod, Masliza; Jacoby, Daniel; White, James; Chiribiri, Amedeo; Helms, Adam; Choudhury, Lubna; Michels, Michelle; Bradlow, William; Salerno, Michael; Dawson, Dana K; Weinsaft, Jonathan W; Berry, Colin; Nagueh, Sherif F; Buccarelli-Ducci, Chiara; Owens, Anjali; Casadei, Barbara; Watkins, Hugh; Weintraub, William S; Neubauer, Stefan.
Afiliação
  • Kramer CM; University of Virginia Health System, Charlottesville, Virginia, USA. Electronic address: ckramer@virginia.edu.
  • DiMarco JP; University of Virginia Health System, Charlottesville, Virginia, USA.
  • Kolm P; MedStar Health Research Institute, Washington, DC, USA.
  • Ho CY; Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Desai MY; Cleveland Clinic, Cleveland, Ohio, USA.
  • Kwong RY; Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Dolman SF; MedStar Health Research Institute, Washington, DC, USA.
  • Desvigne-Nickens P; National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
  • Geller N; National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
  • Kim DY; National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
  • Maron MS; Tufts Medical Center, Boston, Massachusetts, USA.
  • Appelbaum E; Men's Health, Boston, Massachusetts, USA.
  • Jerosch-Herold M; Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Friedrich MG; McGill University, Montreal, Quebec, Canada.
  • Schulz-Menger J; Charité Experimental Clinical Research Center and Helios Clinics Berlin-Buch, Berlin, Germany.
  • Piechnik SK; University of Oxford, Oxford, United Kingdom.
  • Mahmod M; University of Oxford, Oxford, United Kingdom.
  • Jacoby D; Yale University, New Haven, Connecticut, USA.
  • White J; University of Calgary, Calgary, Alberta, Canada.
  • Chiribiri A; King's College, London, United Kingdom.
  • Helms A; University of Michigan, Anne Arbor, Michigan, USA.
  • Choudhury L; Northwestern University, Chicago, Illinois, USA.
  • Michels M; Erasmus University, Erasmus, the Netherlands.
  • Bradlow W; University of Birmingham, Birmingham, United Kingdom.
  • Salerno M; University of Virginia Health System, Charlottesville, Virginia, USA.
  • Dawson DK; University of Aberdeen, Aberdeen, United Kingdom.
  • Weinsaft JW; Weill Cornell Medicine, New York, New York, USA.
  • Berry C; University of Glasgow, Glasgow, United Kingdom.
  • Nagueh SF; Methodist Hospital, Houston, Texas, USA.
  • Buccarelli-Ducci C; University of Bristol, Bristol, United Kingdom.
  • Owens A; University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Casadei B; University of Oxford, Oxford, United Kingdom.
  • Watkins H; University of Oxford, Oxford, United Kingdom.
  • Weintraub WS; MedStar Health Research Institute, Washington, DC, USA.
  • Neubauer S; University of Oxford, Oxford, United Kingdom.
JACC Clin Electrophysiol ; 7(11): 1376-1386, 2021 11.
Article em En | MEDLINE | ID: mdl-34217663
ABSTRACT

OBJECTIVES:

This study sought to identify predictors of major clinically important atrial fibrillation endpoints in hypertrophic cardiomyopathy.

BACKGROUND:

Atrial fibrillation (AF) is a common morbidity associated with hypertrophic cardiomyopathy (HCM). The HCMR (Hypertrophic Cardiomyopathy Registry) trial is a prospective natural history study of 2,755 patients with HCM with comprehensive phenotyping.

METHODS:

All patients received yearly telephone follow-up. Major AF endpoints were defined as requiring electrical cardioversion, catheter ablation, hospitalization for >24 h, or clinical decisions to accept permanent AF. Penalized regression via elastic-net methodology identified the most important predictors of major AF endpoints from 46 variables. This was applied to 10 datasets, and the variables were ranked. Predictors that appeared in all 10 sets were then used in a Cox model for competing risks and analyzed as time to first event.

RESULTS:

Data from 2,631 (95.5%) patients were available for analysis after exclusions. A total of 127 major AF endpoints events occurred in 96 patients over 33.3 ± 12.4 months. In the final model, age, body mass index (BMI), left atrial (LA) volume index, LA contractile percent (active contraction), moderate or severe mitral regurgitation (MR), and history of arrhythmia the most important. BMI, LA volume index, and LA contractile percent were age-dependent. Obesity was a stronger risk factor in younger patients. Increased LA volume, reduced LA contractile percent, and moderate or severe MR put middle-aged and older adult patients at increased risk.

CONCLUSIONS:

The major predictors of major AF endpoints in HCM include older age, high BMI, moderate or severe MR, history of arrhythmia, increased LA volume, and reduced LA contractile percent. Prospective testing of a risk score based on these parameters may be warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Ablação por Cateter Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Revista: JACC Clin Electrophysiol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Ablação por Cateter Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Revista: JACC Clin Electrophysiol Ano de publicação: 2021 Tipo de documento: Article